ckd glp 1 Kidney and Cardiovascular Outcomes Among Patients With Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials GLP-1 and the kidney: from

Additionally, studies have found that the IGF-1 LR3 peptide inhibits protein breakdown, preserving muscle mass during periods of intense training or caloric deficits (3)

For someone already taking a GLP-1 medication, this reinforces the idea that obesity treatment is not cosmetic its a chronic disease treatment and risk-reduction medication. GLP-1s Users Had Lower Rates of Blood Clots, ER Visits, and Death The study analyzed health records from more than 26,000 adults with obesity and at least one autoimmune disease, such as rheumatoid arthritis, psoriatic arthritis, type 1 diabetes, vitiligo, and celiac disease

Accessed May 3, 2022

For treatment via i.p

Largest trial reported increased risk and persistence of CIPN with prophylactic use